Table 2 Treatment effect on secondary outcomes
Outcomes | ||||
|---|---|---|---|---|
Change from baseline to 12 months | ||||
Intervention | Control | Mean difference | P | |
Systolic blood pressure | − 0.17 (18.9) | 3.11 (19.24) | −3.46 (− 5.44 to − 1.48) | 0.001 |
Total/HDL cholesterol | −0.03 (1.3) | 0.01 (1.1) | −0.03 (− 0.17 to 0.10) | 0.633 |
Body mass index (kg/m2) | 0.03 (2.14) | −0.07 (3.76) | −0.08 (− 0.45 to 0.29) | 0.669 |
Modelled cardiovascular risk | −1.24 (8.22) | −0.38 (7.94) | − 0.71 (− 1.46 to 0.041) | 0.064 |
Health status EQ-5D | 0.009 (0.160) | −0.004 (0.157) | − 0.011 (− 0.007 to 0.030) | 0.202 |
Medication taking (MARS) | 0.6 (2.81) | 0.37 (3.18) | −0.26 (− 0.03 to 0.54) | 0.075 |
Satisfaction with health care | 0.27 (0.74) | 0.21 (0.74) | −0.030 (− 0.038 to 0.099) | 0.385 |
Intervention | Control | Relative Risk (95% CI) | P | |
Reaching treatment goals | 182 (36.0) | 136 (26.8) | 1.36 (1.13 to 1.63) | 0.001 |
≥80% visits for medication collection | 87 (15.7) | 79 (14.2) | 1.11 (0.84 to 1.47) | 0.469 |